



## Katerzia™ (amlodipine) – New formulation approval

- On July 8, 2019, the [FDA approved](#) Silvergate Pharmaceuticals' [Katerzia \(amlodipine\)](#) oral suspension, for:
  - Treatment of hypertension in adults and children 6 years and older, to lower blood pressure
  - Symptomatic treatment of chronic stable angina
  - Treatment of confirmed or suspected vasospastic angina
  - To reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented coronary artery disease (CAD) by angiography and without heart failure or an ejection fraction < 40%.
- Amlodipine is also available generically as an oral [tablet](#). The tablet formulation carries the same indications as Katerzia.
- Warnings and precautions for Katerzia include hypotension, increased angina or myocardial infarction, and patients with hepatic failure.
- The most common adverse reaction with amlodipine use is edema which occurs in a dose related manner. Other adverse experiences not dose related but reported with an incidence > 1% are fatigue, nausea, abdominal pain, and somnolence.
- The usual initial antihypertensive oral dose of Katerzia in adult patients is 5 mg orally once daily, and the maximum dose is 10 mg once daily. The recommended dose for adult patients with chronic stable or vasospastic angina or CAD is 5 to 10 mg once daily.
- The effective antihypertensive oral dose in pediatric patients ages 6 to 17 years is 2.5 to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients.
  - Silvergate Pharmaceuticals' launch plans for Katerzia are pending. Katerzia will be available as a 1 mg/mL oral suspension



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.